Radiopharm Theranostics Ltd RADX
Radiopharm Theranostics Ltd (Nasdaq: RADX) is an oncology drug developer. Its lead program, RAD101 (18F-fluoropivalate, FASN-targeting PET imaging agent), is in Phase 2 for diagnosis of suspected recurrent brain metastases from solid tumors. Its next catalyst on record is RAD101: Phase 2b interim data late-breaking oral at SNO26 (November 2026).
Upcoming catalysts
- November 2026RAD101 — Phase 2b interim data late-breaking oral at SNO26
selected for a late-breaking oral presentation at the 31st Annual Meeting of the Society of Neuro-Oncology (SNO26), taking place from November 12-15, 2026 in Philadelphia.
Next further out: RAD101 — Initiate multi-center, multi-country registrational Phase 3 imaging study (Q4 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RAD101 | brain metastases imaging (diagnostic PET, IND pathway) | radiopharmaceutical | Phase 2 |
| RAD204 (Lu177 Nano-mAb PD-L1) | non-small cell lung cancer | radiopharmaceutical | Phase 1 |
| RAD202 (Lu177 Nano-mAb HER2) | HER2 breast and gastric cancer | radiopharmaceutical | Phase 1 |
| RAD301 (68Ga-Trivehexin avb6-integrin imaging) | pancreatic cancer imaging | radiopharmaceutical | Phase 1 |
| RAD402 (Tb161 PSA-mAb) | metastatic or locally advanced prostate cancer | radiopharmaceutical | Phase 1 |
| RV-01 (B7H3 mAb, Radiopharm Ventures) | solid tumors | radiopharmaceutical | Phase 1 |
| RAD302 (Lu177 Trivehexin) | pancreatic, head-neck and lung cancer | radiopharmaceutical | Pre-clinical |
| RAD102 (pivalate therapeutic) | brain tumors | radiopharmaceutical | Pre-clinical |
Recent results and decisions
- Jul 31, 2026positive RAD204 third cohort (90mCi): first patient dosed achieved a durable RECIST-confirmed partial response, tumor shrinkage up to -43%, progression-free at 7+ months.
Data from the third cohort (90mCi) in the Phase 1 study of RAD 204 showed that the first patient dosed at this dose level achieved a durable RECIST-confirmed partial response, with tumor shrinkage up to -43%, still progression free after 7+ months.
Filing - Jul 22, 2026met Final Phase 2b (n=30): 93% PET-MRI concordance across evaluable lesions, meeting primary endpoint; preliminary 86% (12/14) sensitivity; specificity data due Q4 2026.
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial’s primary endpoint.
Filing - Apr 23, 2026completed enrollment Final (30th) patient dosed in the RAD101 Phase 2b imaging trial, completing enrollment.
In April 2026, the Company dosing the final patient in the Phase 2b imaging trial of RAD 101.
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.